Mathieu Clément, Bezin Julien, Pariente Antoine
Inserm, Bordeaux Population Health Research Center, Team AHeaD, UMR 1219, University Bordeaux, Bordeaux, France.
CHU de Bordeaux, Service de Pharmacologie Médicale, Bordeaux, France.
Front Pharmacol. 2023 May 15;14:1129244. doi: 10.3389/fphar.2023.1129244. eCollection 2023.
The COVID-19 epidemic has disrupted care and access to care in many ways. It was accompanied by an excess of cardiovascular drug treatment discontinuations. We sought to investigate a deeper potential impact of the COVID-19 epidemic on antihypertensive drug treatment disruptions by assessing whether the epidemic induced some changes in the characteristics of disruptions in terms of duration, treatment outcome, and patient characteristics. From March 2018 to February 2021, a repeated cohort analysis was performed using French national health insurance databases. The impact of the epidemic on treatment discontinuations and resumption of antihypertensive medications was assessed using preformed interrupted time series analyses either on a quarterly basis. Among all adult patients on antihypertensive medication, we identified 2,318,844 (18.7%) who discontinued their antihypertensive treatment during the first blocking period in France. No differences were observed between periods in the characteristics of patients who interrupted their treatment or in the duration of treatment disruptions. The COVID-19 epidemic was not accompanied by a change in the proportion of patients who fully resumed treatment after a disruption, neither in level nor in trend/slope [change in level: 2.66 (-0.11; 5.42); change in slope: -0.67 (-1.54; 0.20)]. Results were similar for the proportion of patients who permanently discontinued treatment within 1 year of disruption [level change: -0.21 (-2.08; 1.65); slope change: 0.24 (-0.40; 0.87)]. This study showed that, although it led to an increase in cardiovascular drug disruptions, the COVID-19 epidemic did not change the characteristics of these. First, disruptions were not prolonged, and post-disruption treatment outcomes remained unchanged. Second, patients who experienced antihypertensive drug disruptions during the COVID-19 outbreak were essentially similar to those who experienced disruptions before it.
新冠疫情在诸多方面扰乱了医疗服务及就医渠道。疫情期间,心血管药物治疗中断的情况增多。我们试图通过评估疫情是否在中断时长、治疗结果和患者特征方面引发了中断特征的某些变化,来深入探究新冠疫情对降压药物治疗中断的潜在影响。2018年3月至2021年2月,利用法国国家医疗保险数据库进行了重复队列分析。采用预先设定的中断时间序列分析,按季度评估疫情对降压药物治疗中断及恢复的影响。在所有服用降压药物的成年患者中,我们确定有2318844人(占18.7%)在法国首个封锁期内中断了降压治疗。在中断治疗的患者特征或治疗中断时长方面,各时期之间未观察到差异。新冠疫情并未伴随中断后完全恢复治疗的患者比例出现水平或趋势/斜率变化[水平变化:2.66(-0.11;5.42);斜率变化:-0.67(-1.54;0.20)]。中断后1年内永久停药的患者比例结果相似[水平变化:-0.21(-2.08;1.65);斜率变化:0.24(-0.40;0.87)]。本研究表明,尽管新冠疫情导致心血管药物中断增加,但其并未改变这些中断的特征。首先,中断时间没有延长,中断后的治疗结果保持不变。其次,在新冠疫情爆发期间经历降压药物中断的患者与疫情爆发前经历中断的患者基本相似。